Genoil Inc. Files 6-K for June 30, 2024 Period

Ticker: GNOLF · Form: 6-K · Filed: Aug 15, 2024 · CIK: 1261002

Genoil INC 6-K Filing Summary
FieldDetail
CompanyGenoil INC (GNOLF)
Form Type6-K
Filed DateAug 15, 2024
Risk Levellow
Pages1
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 6-k, corporate-update

TL;DR

Genoil Inc. filed its Q2 2024 6-K, confirming 20-F annual report filings.

AI Summary

Genoil Inc. filed a Form 6-K for the period ending June 30, 2024. The filing, submitted on August 15, 2024, indicates that Genoil Inc. is a foreign private issuer and will file annual reports under Form 20-F. The company's principal executive office is located at One Rockefeller Plaza, 11th Floor, New York, NY.

Why It Matters

This filing provides an update on Genoil Inc.'s reporting status and corporate information as of June 30, 2024, which is important for investors tracking the company's regulatory compliance.

Risk Assessment

Risk Level: low — This is a routine periodic filing (6-K) that primarily contains corporate information and does not appear to disclose significant new financial or operational developments.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose of this Form 6-K filing is to report information for the period ending June 30, 2024, as required by the U.S. Securities and Exchange Commission for foreign private issuers.

Which annual report form does Genoil Inc. indicate it will file?

Genoil Inc. indicates it will file annual reports under cover of Form 20-F.

What is the filing date of this Form 6-K?

This Form 6-K was filed as of August 15, 2024.

Where is Genoil Inc.'s principal executive office located?

Genoil Inc.'s principal executive office is located at One Rockefeller Plaza, 11th Floor, New York, NY.

Is Genoil Inc. submitting this Form 6-K in paper format?

The filing indicates that Genoil Inc. is not submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) or Rule 101(b)(7).

Filing Stats: 384 words · 2 min read · ~1 pages · Grade level 15.5 · Accepted 2024-08-15 06:02:39

Filing Documents

Financial Statements

Financial Statements 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Genoil Inc. (Registrant) Date: August 14, 2024 By: /s/ David Lifschultz Name: David Lifschultz Title: CEO 3

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing